The effect of Hemoperfusion in the treatment of covid-19 disease. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group includes 10 patients who enter the study after obtaining the informed consent of the patient or her companion and receive the standard COVID-19 treatment regimen alo
Sponsors
Vice President of Research Guilan university of medical sciences
Eligibility
Sex/Gender
All
Age
12 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with a clinical diagnosis of Covid-19 including respiratory distress with a rate of more than 30 per minute and heart rate more than 125 beats per minute and shortness of breath and oxygen saturation less than 90%, despite receiving oxygen with a positive PCR test and Radiographs in CT SCANING or Chest X Ray, admitted to the intensive care unit. Uncontrollable fevers like T> 39 C. An laboratory evidence of increased inflammatory factors Patients 12 years and older Evidence of severe hemodynamic disturbance using moderate doses of norepinephrine or using a second dose of vasopressor Involvement of more than two vital organs (lungs, kidneys, liver, and heart)
Exclusion criteria
Exclusion criteria: Thrombocytopenia (Plt =20,000) Pregnancy Acute crisis due to sickle cell anemia Evidence of resin sensitivity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improving the patient's clinical condition. Timepoint: Daily. Method of measurement: Evaluation of the presence of Respiratory distress, marked improvement in patients respiration rate, improvement in arterial blood gas condition and self-expression, improvement in patient's heart rate and improvement in patient's inflammatory tests 2-3 days after home perfusion. Inflammatory tests include D.DIMER, IL-6 LDH, FERRITIN, FIBRINOGEN, CRP. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Haghighi
Guilan University of Medical Sciences
Outcome results
None listed